MedTrace Logo

Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment

NCT03422601 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1122

Last updated 2019-02-27

No results posted yet for this study

Summary

The primary objective is to validate that the Immunoscore® test (IS0 to IS4) is able to identify patients with high risk (IS 0-1) of relapse or death whichever occurs first among Stage III patients under oxaliplatin-based adjuvant therapy.

Then the prognostic value of Immunoscore® Colon to predict disease free survival (DFS) will be assessed in Stage III patients under Oxaliplatin treatment in each arm of the IDEA trial (6- months and 3-months treatment).

Finally, the additive value of the Immunoscore® test to stratify the DFS will be evaluated among standard clinical and biological parameters and tumor features.

Conditions

Interventions

DIAGNOSTIC_TEST

Immunoscore test

To identify patients with high risk (IS 0-1) of relapse or death under oxaliplatin-based adjuvant therapy.

Sponsors & Collaborators

  • HalioDx

    collaborator INDUSTRY

  • Methodology and quality of life unit in oncology, University hospital of Besancon

    collaborator UNKNOWN

  • GERCOR - Multidisciplinary Oncology Cooperative Group

    lead OTHER

Principal Investigators

  • Thierry ANDRE, MD · Hôpital Saint Antoine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-13
Primary Completion
2019-06-15
Completion
2019-07-15

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03422601 on ClinicalTrials.gov